Prominex is a transformative point-of-care testing brand that specializes in molecular diagnostic assays for infectious diseases. Founded in 2018, Prominex is dedicated to improving global access to rapid, accurate, and affordable molecular diagnostics. Their Prominex System is a revolutionary solution designed for near-patient care settings, delivering results in just 5 minutes.

The system utilizes novel molecular amplification and detection technologies, allowing for fast, accurate, and easy-to-use multiplexed assays. Prominex initially focuses on developing assays for SARS-CoV-2, Sexually Transmitted Infections, and Respiratory Tract Infections. With a broad IP portfolio, Prominex protects its innovative enzyme, molecular chemistry, and detection technologies.

The leadership team boasts extensive experience in developing best-in-class molecular diagnostic assays and medical devices. Prominex's mission is to provide clinicians with clinically actionable results, broad accessibility, and central lab accuracy, ultimately improving patient care worldwide